• SciSparc subsidiary NeuroThera Labs secured European batch release certification for SCI-110, enabling shipments for its FDA-approved Phase IIb Tourette syndrome trial.
• All three study sites completed initiation activities, positioning the trial to begin enrolling adults; drug shipments are expected in the near term.
• The study will evaluate SCI-110’s efficacy, safety and tolerability in adults with Tourette syndrome.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scisparc Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610220855PRIMZONEFULLFEED9851167) on October 22, 2026, and is solely responsible for the information contained therein.